title: Implantation of the syncardia total artificial heart.
abstract: With advances in technology, the use of mechanical circulatory support devices for end stage heart failure has rapidly increased. The vast majority of such patients are generally well served by left ventricular assist devices (LVADs). However, a subset of patients with late stage biventricular failure or other significant anatomic lesions are not adequately treated by isolated left ventricular mechanical support. Examples of concomitant cardiac pathology that may be better treated by resection and TAH replacement includes: post infarction ventricular septal defect, aortic root aneurysm / dissection, cardiac allograft failure, massive ventricular thrombus, refractory malignant arrhythmias (independent of filling pressures), hypertrophic / restrictive cardiomyopathy, and complex congenital heart disease. Patients often present with cardiogenic shock and multi system organ dysfunction. Excision of both ventricles and orthotopic replacement with a total artificial heart (TAH) is an effective, albeit extreme, therapy for rapid restoration of blood flow and resuscitation. Perioperative management is focused on end organ resuscitation and physical rehabilitation. In addition to the usual concerns of infection, bleeding, and thromboembolism common to all mechanically supported patients, TAH patients face unique risks with regard to renal failure and anemia. Supplementation of the abrupt decrease in brain natriuretic peptide following ventriculectomy appears to have protective renal effects. Anemia following TAH implantation can be profound and persistent. Nonetheless, the anemia is generally well tolerated and transfusion are limited to avoid HLA sensitization. Until recently, TAH patients were confined as inpatients tethered to a 500 lb pneumatic console driver. Recent introduction of a backpack sized portable driver (currently under clinical trial) has enabled patients to be discharged home and even return to work. Despite the profound presentation of these sick patients, there is a 79-87% success in bridge to transplantation.
authors: Division of Cardiothoracic Surgery, Virginia Commonwealth University; dtang@mcvh-vcu.edu.
authors: Daniel G
authors: DG
authors: Tang
authors: Division of Cardiology, Virginia Commonwealth University.
authors: Keyur B
authors: KB
authors: Shah
authors: Division of Cardiology, Virginia Commonwealth University.
authors: Micheal L
authors: ML
authors: Hess
authors: Division of Cardiothoracic Surgery, Virginia Commonwealth University.
authors: Vigneshwar
authors: V
authors: Kasirajan
mesh_terms: D006333:Heart Failure / Q000601:surgery*; D016027:Heart Transplantation / Q000379:methods*; D006354:Heart, Artificial; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000601:surgery*; D008297:Male; D008875:Middle Aged